Articles from Hemogenyx Pharmaceuticals PLC

Collaboration with Vilnius University Hospital Santaros Klinikos on HG-CT-1 Clinical Application and Research

LONDON, UK / ACCESSWIRE / July 13, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has opened its new custom-engineered laboratory at the Mink Building in West Harlem's Manhattanville Factory District of New York City, adjacent to Columbia University and City College. The Company's state-of-the-art research facility includes approximately 10,000 rentable square feet of purpose-built lab space including two clean rooms for cell therapy manufacturing. In addition to continuing and expanding its research, Hemogenyx Pharmaceuticals is now able to manufacture cells in-house, accelerating and simplifying the commercialisation of its major cell therapy product candidates. The Company will first use its clean rooms to produce its HEMO-CAR-T cell therapy for the treatment of acute myeloid leukemia. Hemogenyx Pharmaceuticals is leasing the facility from The Janus Property Company ("Janus").

LONDON, ENGLAND / ACCESSWIRE / July 8, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that following the live investor webinar presented by Dr Vladislav Sandler, Chief Executive Officer and Co-Founder of Hemogenyx Pharmaceuticals held on 6 July 2022, a recording of the webinar is now available to view on the Company's YouTube channel at https://youtu.be/LFH95Zw8e6Y

LONDON, ENGLAND / ACCESSWIRE / July 1, 2022 / Hemogenyx Pharmaceuticals plc announces that its registered office address has changed with immediate effect to 6th Floor,60 Gracechurch Street, London, EC3V 0HR,United Kingdom.

LONDON, ENGLAND / ACCESSWIRE / June 30, 2022 / Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

LONDON, UK / ACCESSWIRE / June 27, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that Dr Vladislav Sandler, Chief Executive Officer & Co-Founder of Hemogenyx Pharmaceuticals, will host a live investor webinar on 6 July 2022 at 16:00 BST at which he will present an overview of the Company's activities and immediate future directions of its work, and will answer questions about the Company's current activities. If you would like to register for the webinar, please follow this link:

LONDON, UK / ACCESSWIRE / June 7, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2021, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy were posted to shareholders today and are available on the Company's website at https://hemogenyx.com/investors/annual-and-half-year-reports, and the 2021 Equity Incentive Plan with Non-Employee Sub-Plan (relating to AGM Resolution 5) is available on the Company's website athttps://hemogenyx.com/investors/company-profile/company-information.

LONDON, UK / ACCESSWIRE / May 30, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,284,889 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 1.44p per share. Following this transaction, Mr Wright has a total beneficial interest in 4,000,000 Ordinary Shares, representing approximately 0.41 per cent of the Company's issued share capital.

LONDON, UK / ACCESSWIRE / May 16, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce its participation in the Immuno-Oncology Summit Europe 2022, at which Dr Vladislav Sandler will make a presentation entitled "Anti-FLT3 CAR-T and Bispecific Antibody Therapies for Effective Elimination of AML and Conditioning for Hematopoietic Stem Cell Transplantation". The conference assembles a wide range of thought leaders from both

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

LONDON, UK / ACCESSWIRE / March 16, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept ("POC") for its Chimeric Bait Receptor ("CBR") platform technology. The Company has filed a seminal provisional patent application protecting its rights to the intellectual property ("IP") covering CBR. CBR is a

LONDON, UK / ACCESSWIRE / February 16, 2022 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration ("FDA") that the proposed pre-Investigational New Drug ("pre-IND") meeting relating to the Company's lead product candidate Chimeric Antigen Receptor ("CAR")

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Hemogenyx Pharmaceuticals Partnership with Selexis SA to Advance CDX Development Hemogenyx Pharmaceuticals and Selexis SA ("Selexis") will leverage Selexis' SUREtechnology Platform™ of protein expression technologies and modular workflows to advance the Company's acute myeloid leukemia CDX bispecific antibody toward human trials LONDON, UK / ACCESSWIRE /

LONDON, UK / ACCESSWIRE / January 5, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022. As part of the Company's presentation, Dr.

Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme LONDON, UK / ACCESSWIRE / December 20, 2021 / Hemogenyx Pharmaceuticals will leverage WuXi Advanced Therapies' ("WuXi ATU") plasmid and lentiviral vector manufacturing platforms, including integrated testing, to accelerate HEMO-CAR-T programme for acute myeloid leukaemia ("AML") toward phase I clinical

LONDON, UK / ACCESSWIRE / December 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce significant progress in relation to moving its lead product candidate Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") toward clinical trials. The Company has applied for a pre-Investigational New Drug ("PIND") application meeting with the FDA

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Convertible Loans Repayment LONDON, UK / ACCESSWIRE / November 24, 2021 / As originally announced in October 2018, Hemogenyx-Cell S.A. ("Hemogenyx-Cell") and Immugenyx LLC ("Immugenyx"), each wholly-owned subsidiaries of Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, each entered into

LONDON, UK / ACCESSWIRE / October 18, 2021 / Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company ("Janus") for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of New York, adjacent to Columbia University and City College. The Company's new 10,000 rentable square feet lab will include two clean rooms purpose-built by Janus, allowing it to pursue

LONDON, UK / ACCESSWIRE / October 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the "Agreement") with the global biopharmaceutical company Eli Lilly and Company ("Lilly"). Under this Agreement, Lilly grants the Company an exclusive worldwide licence to certain intellectual property developed by Lilly

Interim Results for the period ended 30 June 2021 LONDON, UK / ACCESSWIRE / September 30, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the StandardListed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces unaudited interim results for the six-month period ended 30 June 2021. All financial amounts are stated in GBP British pounds unless otherwise indicated. Key Highlights - Completed

LONDON, UK / ACCESSWIRE / September 2, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a further patent application entitled MONOCLONAL ANTIBODIES TO HUMAN FLT3/FLK2 RECEPTOR PROTEIN has been approved and issued by the United States Patent and Trademark Office. The patent was issued on 31 August 2021 as Patent Number US 11,104,738.

Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management. LONDON, UK / ACCESSWIRE / July 26, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Dr Alan E. Walts as a Board observer and

LONDON, UK / ACCESSWIRE / July 2, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce that a new corporate presentation is available at http://www.rns-pdf.londonstockexchange.com/rns/0316E_1-2021-7-2.pdf. Enquiries: Hemogenyx Pharmaceuticals plc https://hemogenyx.comDr Vladislav Sandler, Chief Executive Officer &

LONDON, ENGLAND / ACCESSWIRE / June 25, 2021 / Hemogenyx Pharmaceuticals plc (OTC PINK:HOPHF) (LSE:HEMO) is pleased to announce that, at the Annual General Meeting ('AGM') held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below. AGM Voting Results Ordinary ResolutionsVotes for% of votes cast forVotes Against% of votes cast againstTotal votes castTotal votes cast as % of ISC (1)Votes

LONDON, UK / ACCESSWIRE / June 15, 2021 / Hemogenyx Pharmaceuticals plc ('Hemogenyx Pharmaceuticals' or the 'Company')(LSE:HEMO) announces that as a result of the continuation in force of COVID-19 restrictions to 19 July announced by the UK Government, and in order to protect the health and safety of the Company's Shareholders and Directors, the Company's Annual General Meeting to be held on 25 June 2021 (the 'AGM') will be held as a closed

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") U.S. Approval and Issuance of CDX Antibody Patent LONDON, UK / ACCESSWIRE / June 2, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC

Posting of Annual Report & Notice of Annual General Meeting LONDON, UK / ACCESSWIRE / May 28, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2020, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy were posted to shareholders today and are available on the Company's website:

LONDON, UK / ACCESSWIRE / May 28, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 May 2021 consists of 979,749,321 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 979,749,321. The figure of 979,749,321

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY

LONDON, UK / ACCESSWIRE / May 19, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,088,120 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an average price of 1.8288 pence per share. Following this transaction, Mr Wright has a total beneficial interest in

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, UK / ACCESSWIRE / May 12, 2021 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO) announces that it has today published a supplementary prospectus approved by the FCA (the

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. LONDON, UK / ACCESSWIRE / May 5, 2021 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the

LONDON, UK / ACCESSWIRE / April 30, 2021 / THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Final Results for the Year Ended 31 December 2020 Hemogenyx Pharmaceuticals plc

LONDON, UK / ACCESSWIRE / April 30, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 30 April 2021 consists of 494,343,020 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 494,343,020. The

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Conversion of Convertible Loan Notes LONDON, UK / ACCESSWIRE / April 26, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. LONDON, UK / ACCESSWIRE / April 16, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has received a conversion

LONDON, UK / ACCESSWIRE / April 14, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces an update on negotiations regarding the future development of its leading product candidate CDX bispecific antibody ("CDX") for the treatment of acute myeloid leukemia ("AML") and other potential applications. On 13 January 2021, the Company